S. Kaneko

发表

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

H. Ueno, Y. Shimada, N. Hiraoka, 2012, Neuroendocrinology.

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

P. Galle, Ruifeng Xu, J. Llovet, 2022, Annals of Oncology.